Selvita

Historical price data

Selvita is a key player in the Central and Eastern European life sciences sector, combining a service-based contract research organization (CRO) business with proprietary drug development. The company's core expertise lies in integrated drug discovery, medicinal chemistry, and biology, which it applies to internal oncology programs and external partnerships. Its strategic direction involves advancing its pipeline of small molecule inhibitors while expanding its global CRO footprint. Key achievements include establishing long-term collaborations with major pharmaceutical companies and progressing several proprietary assets into clinical and pre-clinical stages.

An integrated drug discovery platform combining medicinal chemistry, computational design, biology, biochemistry, and DMPK services to enable both internal pipeline development and external client projects.

Selvita competes with large global CROs (e.g., Charles River, Evotec) in services and with numerous biotechs in oncology drug development. Its differentiation lies in its deep oncology expertise, integrated discovery platform, favorable cost structure from its Polish base, and a hybrid model that uses service revenue to fund proprietary innovation.